Andrew Jackson

Lundbeck is a research based, Danish Pharmaceutical Company with a longstanding commitment to neuroscience.

Andrew became Managing Director for both UK and Ireland in September 2024 after working for Lundbeck for 15 years and acting as Country Manager for the UK since 2019.  He began his career as a Primary Care Sales Representative at Wyeth in 2003 and held roles of increasing responsibility before moving to Lundbeck in 2009.  There, he has been responsible for driving growth and advancing patient access for Lundbeck’s brands as well as transforming the organisation for the future.

As a representative of Smaller Companies on the ABPI Board, Andrew is keen to ensure that the voice of smaller companies is heard and that innovation across our sector can flourish.